论文部分内容阅读
研究CTLA4Ig对异体复合组织移植的免疫抑制作用。方法 :以BN大鼠为供体 ,Lewis大鼠为受体进行异体耳廓移植 ,术后分组应用不同剂量CTLA4Ig治疗 ,观察移植耳廓的排斥反应及存活时间 ,检测术后血清IL - 2含量变化。结果 :对照组平均存活 (7.8± 1.9)d ,CTLA4Ig 0 .1mg/kg·d治疗组存活 (8.1± 1.6 )d ,与对照组比无明显差异 (P >0 .0 5 ) ;1.0mg/kg·d组与 5 .0mg/kg·d组分别为 (15 .5± 2 .3)d与 (2 8.8± 3.6 )d ,异体耳廓的存活时间显著延长 (P <0 .0 1) ,且IL - 2含量较对照组明显下降。结论 :CTLA4Ig能延长异体耳廓复合组织移植后的存活 ,其疗效与剂量相关。
To study the immunosuppressive effect of CTLA4Ig on allogeneic tissue transplantation. Methods: BN rats were used as donors and Lewis rats were used as recipients for allogenic auricle transplantation. The rats were treated with different doses of CTLA4Ig after transplantation. The rejection and survival time were observed, and the levels of IL - 2 Variety. Results: The average survival rate of the control group (7.8 ± 1.9) days and CTLA4Ig0.1mg / kg · d treatment group (8.1 ± 1.6 days) was no significant difference compared with the control group (P> 0.05) (15.5 ± 2.3 days) and (8.8 ± 3.6) days in the group of kg · d and 5.0 mg / kg · d, respectively. The survival time of allogeneic pinna was significantly longer (P <0.01) , And the content of IL - 2 decreased significantly compared with the control group. Conclusion: CTLA4Ig can prolong the survival of allogeneic auricular compound tissue transplantation, and its efficacy is dose-dependent.